0001415889-24-009030.txt : 20240325
0001415889-24-009030.hdr.sgml : 20240325
20240325160738
ACCESSION NUMBER: 0001415889-24-009030
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240321
FILED AS OF DATE: 20240325
DATE AS OF CHANGE: 20240325
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Wagner Paul A.
CENTRAL INDEX KEY: 0001612842
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38052
FILM NUMBER: 24779272
MAIL ADDRESS:
STREET 1: C/O PFENEX INC.
STREET 2: 10790 ROSELLE STREET
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Forte Biosciences, Inc.
CENTRAL INDEX KEY: 0001419041
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 261243872
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 3060 PEGASUS PARK DRIVE
STREET 2: BUILDING 6
CITY: DALLAS
STATE: TX
ZIP: 75247
BUSINESS PHONE: (310) 618-6994
MAIL ADDRESS:
STREET 1: 3060 PEGASUS PARK DRIVE
STREET 2: BUILDING 6
CITY: DALLAS
STATE: TX
ZIP: 75247
FORMER COMPANY:
FORMER CONFORMED NAME: Tocagen Inc
DATE OF NAME CHANGE: 20071120
4
1
form4-03252024_080331.xml
X0508
4
2024-03-21
0001419041
Forte Biosciences, Inc.
FBRX
0001612842
Wagner Paul A.
C/O FORTE BIOSCIENCES, INC.
3060 PEGASUS PARK DR., BLDG 6
DALLAS
TX
75247
true
true
false
false
SEE REMARKS
0
Stock Option (right to buy)
0.69
2024-03-21
4
A
0
1100000
0
A
2034-03-21
Common Stock
1100000
1100000
D
Subject to the Reporting Person continuing to be a Service Provider (as defined in the amended and restated 2021 Equity Incentive Plan) through each applicable vesting date, twenty five percent (25%) of the shares subject to the option shall vest on the one year anniversary of the Vesting Commencement Date and one forty-eighth (1/48th) of the total shares subject to the option shall vest every month thereafter such that all shares shall be fully vested on the four year anniversary of the Vesting Commencement Date. "Vesting Commencement Date" shall mean March 21, 2024.
CEO, Secretary and Chair of the Board
/s/ Paul A. Wagner, Ph.D.
2024-03-25